dc.creatorBucaretchi F.
dc.creatorDragosavac S.
dc.creatorVieira R.J.
dc.date2003
dc.date2015-06-30T17:31:04Z
dc.date2015-11-26T14:09:57Z
dc.date2015-06-30T17:31:04Z
dc.date2015-11-26T14:09:57Z
dc.date.accessioned2018-03-28T21:10:35Z
dc.date.available2018-03-28T21:10:35Z
dc.identifier
dc.identifierJornal De Pediatria. , v. 79, n. 6, p. 519 - 524, 2003.
dc.identifier217557
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-1642419619&partnerID=40&md5=9dec5c7614200a93465a525810f226b6
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/102410
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/102410
dc.identifier2-s2.0-1642419619
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1241383
dc.descriptionObjectives: To study acute exposure to imidazoline derivatives in 72 children younger than 15 years of age, followed-up from January 1994 to December 1999. Methods: This is a retrospective study of 72 patients with age between 2 months and 13 years (median 2 years; 25-75% = 1 to 3 years old) exposed to naphazoline (N=48), fenoxazoline (N=18), oxymetazoline (N=5) and tetrahydrozoline (N=1), through oral (N=46), nasal (N=24) or unknown (N=2) routes. Results: Fifty-seven children developed clinical manifestations such as somnolence (N=34/57), sweating (N=20/57), pallor (N=17/ 57), hypothermia (N=16/57), bradycardia (N=13/57), cool extremities (N=9/57), restlessness (N=7/57), tachycardia (N=6/57), vomiting (N= 5/57), irregular respiratory pattern and apnea (N= 5/57), miosis/ mydriasis (N=4/57). Naphazoline was the active ingredient most frequently involved (N=47), followed by phenoxazoline (N=5) and oxymetazoline (N=4). The onset of clinical manifestations was rapid, beginning within 2 hours after exposure in 32/57 children, Only supportive measures were employed, with one child requiring mechanical ventilation after accidental naphazoline ingestion. In most of the children resolution of symptoms occurred within 24 hours (N= 39/57). No deaths were observed. Patients exposed to naphazoline (N=47/48) presented a higher frequency of clinical signs of poisoning in comparison with those exposed to phenoxazoline (N=5/18) (p < 0.001). There were no significant differences in the frequency of patients who presented clinical manifestations considering the route of exposure [oral (N=34/46), nasal (N=21/24); p=0.31]. Conclusions: Most children (especially those younger than 3 years) exposed to imidazoline derivatives (especially naphazoline) presented early signs of poisoning regardless of the exposure route (nasal or oral). The main signs observed were nervous system, cardiovascular and respiratory depression. Most children showed complete resolution of the symptoms within 24 hours.
dc.description79
dc.description6
dc.description519
dc.description524
dc.descriptionEllenhorn, M.J., Over the counter products (1997) Ellenhorn's Medical Toxicology, Diagnosis and Treatment of Human Poisoning. 2 a Ed., pp. 971-1035. , Ellenhorn MJ. Baltimore: Lippincott, Williams & Wilkins
dc.descriptionInnes, I.R., Nickerson, M., Drugs acting on postganglionic adrenergic nerve endings and structures innervated by them (sympathomimetic drugs) (1970) The Pharmacological Basis of Therapeutics. 4 a Ed., pp. 478-523. , Goodman LS, Gilman A. New York, NY: The MacMillan Company
dc.descriptionKorolkovas, A., Fármacos do Aparelho Respiratório (2000) Dicionário Terapêutico Guanabara. Edição 1999/2000, , Rio de Janeiro: Guanabara Koogan
dc.descriptionImidazoline derivatives: Fenoxazoline, naphazoline, oxymethazoline, tetrahydrozoline and xylometazoline (1982) Martindale - The Extra Pharmacopoeia. 28 a Ed., p. 13. , Reynolds JEF, Prasad AB, editores. Londres: The Pharmaceutical Press
dc.descriptionRumack, B.H., (2000) POISINDEX® Toxicologic Substance Identification. MICROMEDEX® Health Care Series, 106. , Denver: MICROMEDEX® Inc
dc.descriptionSchvartsman, S., (1988) Medicamentos em Pediatria, Monografias Médicas Série "Pediatria", Volume XV. 3 a Ed., 15. , 1 a reimpressão. São Paulo (SP): Sarvier
dc.descriptionHiggins, G.L., Campbell, B., Wallace, K., Talbot, S., Pediatric poisoning from over-the-counter imidazoline-containing products (1991) Ann Emerg Med, 20, pp. 655-658
dc.descriptionHoffman, B.B., Lefkowitz, R.J., Cathecolamines, sympathomimetic drugs and adrenergic receptor antagonists (1996) The Pharmacological Basis of Therapeutics. 9 a Ed., pp. 199-248. , Hardman JG, Limbrid LE, Molinoff PB, Ruddon RW, Gilman AG, editores. Goodman & Gilman. McGraw-Hill
dc.descriptionMahieu, L.M., Rooman, R.P., Goossens, E., Imidazoline intoxication in children (1993) Eur J Pediatr, 152, pp. 944-946
dc.descriptionVitezic, D., Rozmanic, V., Franulovic, J., Ahel, V., Matesic, D., Naphazoline nasal drops intoxication in children (1994) Arch Hig Rada ToksiKol, 45, pp. 25-29
dc.descriptionBruni, R., L'avvelenamento acuto da derivati imidazolinici per uso topico endonasale nell'infanzia (1970) Minerva Pediatr, 22, pp. 2293-2367
dc.descriptionClaudet, I., Fries, F., Danger des vasoconstricteurs nasaux chez le nourisson. A propos d'une observation (1997) Arch Pédiatr, 4, pp. 538-541
dc.descriptionGlazener, F., Blake, K., Gradman, M., Bradycardia, hypotension and near syncope associated with Afrin® (oxymetazoline) nasal spray (1983) N Engl J Med, 309, p. 731
dc.descriptionGreenstein, N.M., Friedman, H.T., Reactions following use of nasal decongestants (1955) JAMA, 157, p. 1153
dc.descriptionKrenzelok, E.P., Accidents and emergencies (acute poisonings) (1996) Gellis &amp
dc.descriptionKagan's Current Pediatric Therapy. 15 a Ed., pp. 723-732. , Burg DF, Inglfinger JR, Wald ER, Polin RA, editores. Filadélfia: W. B. Saunders Co
dc.descriptionSöderman, P., Sahlberg, D., Wiholm, B.E., CNS Reactions to nose drops in small children (1984) Lancet, 1, p. 573
dc.descriptionKlein-Schwartz, W., Trends and toxic effects from pediatric clonidine exposures (2002) Arch Pediatr Adolesc Med, 156, pp. 392-395
dc.descriptionLewin, N.A., Antihypertensive Agents (1994) Goldfrank's Toxicologic Emergencies. 5 a Ed., pp. 395-407. , Goldfrank LR. Londres: Prentice-Hall International Inc
dc.descriptionLiebelt, E.L., The use of naloxone for resuscitation of non-opioid toxicity (2003) Abstracts of the XXIII Congress of the European Association of Poison Centres and Clinical Toxicologists (EAPCCT), , May 20-23
dc.descriptionRoma- Italy: abstract n. 30
dc.descriptionRudolf, J., Viccellio, P., Clonidine (1998) Emergency Toxicology. 2 a Ed., pp. 703-706. , Viccellio P. Filadélfia: Lippincott-Raven Publishers
dc.descriptionWiley, J.F., Wiley, C.C., Torrey, S.B., Henregit, F.M., Clonidine poisoning in young children (1990) J Pediatr, 116, pp. 654-657
dc.descriptionThe AACT/EAPCCT Position Statements on Gastrointestinal Decontamination. Gastric lavage (1997) J Toxicol Clin Toxicol, 35, pp. 711-720
dc.descriptionThe AACT/EAPCCT Position Statements on Gastrointestinal Decontamination. Single-dose activated charcoal (1997) J Toxicol Clin Toxicol, 35, pp. 721-742
dc.languagept
dc.publisher
dc.relationJornal de Pediatria
dc.rightsaberto
dc.sourceScopus
dc.titleAcute Exposure To Imidazoline Derivatives In Children [exposição Aguda A Derivados Imidazolínicos Em Crianças]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución